1. Indications and Usage
\nALK-Positive Non-Small Cell Lung Cancer (NSCLC):
\nIndicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have not received prior ALK inhibitor therapy or who have disease progression on or intolerant to crizotinib.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Oral Use ONLY. Can be taken with or without food.
\nRecommended Dosage (Two-Part Dosing):
\nPart 1: 90 mg once daily for the first 7 days.
\nPart 2: If the 90 mg dose is tolerated, increase the dose to 180 mg once daily starting on Day 8.
\nRationale: The initial 7-day lead-in period is intended to monitor for initial adverse reactions (especially pulmonary toxicity) before reaching the full therapeutic dose.
\nMissed Dose\/Vomiting:
\nIf a dose is missed or vomiting occurs, do not retake the dose; take the next scheduled dose at the regular time.
\n3. Mechanism of Action
\nALK Inhibition:
\nBrigatinib is a potent inhibitor of wild-type ALK and mutant ALK proteins (including crizotinib-resistant mutations).
\nTumor Growth Inhibition:
\nIt inhibits the phosphorylation of ALK and downstream signaling proteins (such as STAT3, AKT, and ERK), thereby blocking cell proliferation and inducing apoptosis in ALK-expressing tumor cells.
\n4. Safety and Warnings
\nPulmonary Toxicity (Pneumonitis\/ILD):
\nNon-infectious pneumonia and Interstitial Lung Disease (ILD) can occur, typically within the first week of treatment. Monitor patients for pulmonary symptoms (cough, dyspnea, hypoxia). Discontinue or interrupt treatment if severe.
\nHypertension:
\nHypertension can occur early during treatment. Monitor blood pressure weekly for the first month and as clinically indicated.
\nBradycardia:
\nCan cause bradycardia and heart block. Monitor heart rate and blood pressure, especially in patients taking medications known to cause bradycardia.
\nCreatine Kinase (CPK) Elevation:
\nAsymptomatic increases in CPK can occur. Monitor CPK levels prior to initiation and periodically during treatment.
\nPancreatic Enzyme Elevations:
\nIncreases in amylase and lipase can occur. Monitor serum amylase and lipase levels.
\n5. Adverse Reactions
\nMost Common:
\nGeneral: Nausea, diarrhea, diarrhea, fatigue, rash, cough, dyspnea.
\nLaboratory Abnormalities: Increased CPK, increased ALT\/AST, increased amylase\/lipase, hypertension.
\n6. Drug Interactions
\nCYP3A Substrate:
\nBrigatinib is metabolized by CYP3A.
\nStrong CYP3A Inhibitors (e.g., Clarithromycin, Ketoconazole): Avoid co-administration. If unavoidable, reduce the Brigatinib dose.
\nStrong CYP3A Inducers (e.g., Rifampin, Phenobarbital): Avoid co-administration as they significantly decrease Brigatinib exposure, leading to potential treatment failure.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Brigatinib.
\nAppearance: Yellow, oval, film-coated tablets (90 mg and 180 mg strengths available).
\nStorage: Store at 20\u00b0C\u201325\u00b0C (68\u00b0F\u201377\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u5b89\u4f2f\u745e\u00ae(Alunbrig\u00ae)
\nGeneric Name: Brigatinib
\nStrength: 180mg per tablet, 7 tablets per blister, 28 tablets per box (4 blisters\/box)
\nManufacturer: Takeda Pharmaceuticals International GmbH
\nMarketing Authorization Holder: Takeda (China) International Trading Co., Ltd.
\nApproval Date in China: March 22, 2022
\nRegistration Number: \u56fd\u836f\u51c6\u5b57HJ20220009
\nStorage: Store sealed below 30\u2103, avoid direct sunlight and dampness; keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Brigatinib \uff08Alunbrig\uff09<\/p>\n","protected":false},"featured_media":3743,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[74],"product_cat":[27],"product_tag":[],"class_list":["post-3742","product","type-product","status-publish","has-post-thumbnail","product_brand-takeda","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n